Commonwealth Diagnostics International (CDI)
Commonwealth Diagnostics International (CDI): Leading the Way in GI Health Diagnostics
Commonwealth Diagnostics International (CDI) is a premier provider of diagnostic solutions, focusing on helping physicians identify and diagnose the root causes of digestive discomfort and functional gastrointestinal (GI) disorders. With a patient-first approach, CDI has developed a comprehensive portfolio of cutting-edge diagnostic tools designed to enhance the accuracy and timeliness of GI health assessments.
About Commonwealth Diagnostics International (CDI)
Founded in 2015 in Salem, Massachusetts, CDI operates from its CLIA-certified laboratory and is an FDA-registered, ISO 13485-certified medical device manufacturer. CDI partners with leading health systems, hospitals, and private practices around the globe, offering innovative, cost-effective diagnostic solutions that help healthcare professionals develop more efficient treatment plans for GI-related issues.
CDI’s Comprehensive Diagnostic Portfolio
CDI specializes in providing non-invasive, at-home diagnostic tests that help identify common sources of digestive distress. Their portfolio includes hydrogen and methane breath tests for Small Intestinal Bacterial Overgrowth (SIBO) and Intestinal Methanogen Overgrowth (IMO). Additionally, CDI offers tests for fructose, lactose, and sucrose malabsorption, all designed to assist physicians in diagnosing a variety of functional GI disorders.
By offering these easy-to-use tests, CDI ensures that healthcare providers have access to accurate, timely results. This leads to faster diagnoses and more tailored treatment plans that address the unique needs of each patient.
Precision and Innovation in GI Diagnostics
CDI’s approach to diagnostics is built on a foundation of precision, efficiency, and quality. The company utilizes cutting-edge gas chromatography (GC) technology, developed in collaboration with a leading manufacturer. This innovative system integrates dual-detector technology and custom-designed components to enhance the accuracy and sensitivity of the instruments, allowing for precise measurement of hydrogen (H2), methane (CH4), and carbon dioxide (CO2) during breath testing.
This technological advancement enables CDI to provide healthcare providers with faster, more reliable test results, ensuring that patients receive the best possible care. With streamlined sample processing and a focus on quality assurance, CDI consistently delivers results that meet the highest industry standards.
Patient-Centric Solutions for GI Health
At the heart of CDI’s mission is a commitment to improving patient outcomes. Their diagnostic tests not only help identify the causes of GI distress but also support the development of personalized treatment plans. By guiding practitioners in dietary modifications, nutritional supplementation, and other therapeutic approaches, CDI helps to create meaningful and lasting improvements in GI health.
Commonwealth Diagnostics Testing Standards
CDI is dedicated to maintaining the highest standards of accuracy and reliability in its diagnostic services. Their advanced gas chromatography systems, built by Agilent Technologies, offer an exceptional linear range for hydrogen and methane detection (3 to 1000 ppm) and carbon dioxide detection (0.2 to 10%). These systems maintain a precision rate of over 90% accuracy, ensuring reliable results for healthcare providers and patients alike.
The company follows strict calibration protocols using National Institute of Standards and Technology (NIST) traceable gas standards. CDI also adheres to the North American Consensus for Breath Testing, developed by global clinical scientists, further ensuring the accuracy of its tests.
To maximize throughput and consistency, CDI’s laboratory employs fully automated sample extraction systems. Their exclusive collection tube preserves breath samples for up to two weeks, even under extreme temperatures (-4°F to 104°F). By using high-purity reference gasses, CDI improves detection limits and ensures that its instrumentation consistently delivers accurate results.
Certifications and Accreditations
Commonwealth Diagnostics International is committed to maintaining the highest standards of quality and safety in its diagnostic services. The company is:
- CLIA Certified
- ISO 13485 Certified
- FDA Registered
These certifications underscore CDI’s dedication to providing reliable, high-quality diagnostic solutions that support improved patient outcomes in the field of GI health.
Commonwealth Diagnostics International is at the forefront of GI health diagnostics, offering innovative, patient-centered solutions that help healthcare providers accurately diagnose and treat functional gastrointestinal disorders. Through its advanced diagnostic tools, cutting-edge technology, and commitment to quality, CDI is making significant strides in improving digestive health outcomes worldwide. Whether through its non-invasive breath tests or the patient-focused MyGiHealth app, CDI ensures that both physicians and patients have the tools they need for effective, timely care.
Show more